Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06267560 · ClinicalTrials.gov registry record · Phase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD
A Phase 3 study of Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 422
- Enrollment target
- 20
- Study locations
NCT06267560 is a Phase 3 study of Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 422 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT06267560, a Phase 3 study of Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 422 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) 80 mg s.c. QM compared with placebo s.c. QM in US Black/African American and Hispanic participants with established ASCVD and elevated levels of Lp(a) who are treated for cardiovascular (CV) risk factors according to local practice/guidelines for the reduction of cardiovascular risk.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TQJ230
Study Locations (20)
California
- National Heart Institute - Beverly Hills
- Alliance Clinical - Canoga Park
- Valley Clinical Trials Inc - Covina
- NICRs Research Center - Garden Grove
- University of Calif Irvine Med Cntr - Irvine
- Long Beach Clinical Trials - Long Beach
- Angel City Research Inc - Los Angeles
- Velocity Clinical Trials - Los Angeles
- California Medical Research Associates Inc - Northridge
- Stanford University Medical Center - Palo Alto
- Acclaim Clinical Research - San Diego
Florida
- Excel Medical Clinical Trials LLC - Boca Raton
- C and A Clinical Trials - Cape Coral
- Proactive Clinical Research - Fort Lauderdale
- National Research Institute - Hialeah
- Sister Life Research Inc - Hialeah
- Zenith Clinical Research - Hollywood
Alabama
- Parkway Medical Center - Birmingham
Arizona
- Synexus - Glendale
Arkansas
- Cardiology and Medicine Clinic PA - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2024-04-24 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06267560
The ClinicalTrials.gov registry entry for NCT06267560 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 422 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06267560 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06267560 about?
NCT06267560 is a clinical study titled "Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD". Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) 80 mg s.c. QM compared with placebo s.c. QM in US Black/African American and Hispanic participants with established ASCVD and elevated level...
What is the current status of trial NCT06267560?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 422 participants. The study started on 2024-04-24. Estimated completion is 2026-03-31.
What conditions does trial NCT06267560 study?
This clinical trial studies the following conditions: Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT06267560?
The interventions under investigation include: Placebo (DRUG), TQJ230 (DRUG).
Who is sponsoring clinical trial NCT06267560?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06267560 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.